Mercer Global Advisors
ZNTL icon

Mercer Global Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Mercer Global Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194 Buy
+40
New +$160 ﹤0.01% 5920

Other funds holding ZNTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mercer Global Advisors's ZNTL Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 40 shares worth $194. The stake represents ﹤0.01% of the portfolio and ranks #5920 among its holdings.

65 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Mercer Global Advisors held 40 shares of Zentalis Pharmaceuticals worth $194 as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Mercer Global Advisors position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5920 holding.
  • 65 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.